Predicting Alzheimer's disease with practice effects, APOE genotype and brain metabolism

Neurobiol Aging. 2022 Apr:112:111-121. doi: 10.1016/j.neurobiolaging.2021.12.011. Epub 2022 Jan 2.

Abstract

After the paper Cognition or genetics. Predicting progression to Alzheimer's disease with practice effects, APOE genotype and brain metabolism [Neurobiol Aging, 2018; 71:234-240] was published, we identified a coding error of one of the variables analyzed. To correct, update and expand the previous work, we compared simple and complex regression-based Reliable Change Index (RCIRB) to analyze the risk of progression to AD (AD-risk) after six years using either delayed recall or recognition scores. Auditory Verbal Learning Test scores at six months for 394 individuals with normal cognition from the ADNI were used to build the regression. In 816 individuals with amnestic mild cognitive impairments, the AD-risk was associated with age, brain metabolism, APOE-ε4, recognition hits, the discrimination index, and low practice effects in the complex RCIRB only. The complex RCIRB outperformed the simple RCIRB. Small correlations were found between practice effects and both Aβ (highest r = 0.218) and TAU (highest r = -0.183). RCIRB are computationally simple and provide sensitive AD-risk estimates in combination with APOE-ε4 and FDG-PET.

Keywords: Biomarkers; Memory; Practice effects; Recognition; Reliable change.

MeSH terms

  • Alzheimer Disease* / diagnosis
  • Alzheimer Disease* / genetics
  • Alzheimer Disease* / metabolism
  • Amyloid beta-Peptides / metabolism
  • Apolipoprotein E4 / genetics
  • Apolipoprotein E4 / metabolism
  • Apolipoproteins E / genetics*
  • Apolipoproteins E / metabolism
  • Brain / diagnostic imaging
  • Brain / metabolism
  • Genotype
  • Humans
  • Neuropsychological Tests

Substances

  • Amyloid beta-Peptides
  • ApoE protein, human
  • Apolipoprotein E4
  • Apolipoproteins E